Pulmonx (LUNG) Stock Analysis & AI Equity Report
Pulmonx (LUNG) overview
Pulmonx (LUNG) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 90.5m and operating profit of USD -53.7m; the year-end share price was 2.21 USD and market capitalisation was USD 92.1m. Pulmonx is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pulmonx's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Pulmonx
Pulmonx provides minimally invasive treatments for patients with severe emphysema. Its products include the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the LungTraX Platform, which helps identify patients who may be eligible for Zephyr treatment. The company also manufactures the AeriSeal System, a polymer foam under clinical investigation. It sells directly in the United States and uses direct and distributor-based sales internationally.
Generate the Pulmonx report
Pulmonx is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Pulmonx and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Pulmonx
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.